Response seeks US OK for flu test:
This article was originally published in Clinica
Response Biomedical has filed a US 510(k) application to market its rapid, point-of-care test for influenza A and influenza B. The qualitative test will run on the the Vancouver, Canada-based firm's RAMP platform and will be marketed and sold exclusively by 3M Health Care as the 3M Rapid Detection Flu A+B Test. It uses as specimens nasal wash, nasal swab, nasopharyngeal aspirate and nasopharyngeal swab.